Cost-effectiveness analysis of larotrectinib vs standard of care for treatment of metastatic NTRK fusion colorectal cancer
{{output}}
Background: This study evaluates the cost-effectiveness of larotrectinib compared to the standard of care for treating metastatic NTRK fusion colorectal cancer (CRC) from the perspective of healthcare payers in China. ... ...
